Table 1.
Baseline Patient Characteristics
| CLL (n=16) | DLBCL* (n=6) | MCL (n=3) | Richter’s (n=9) | All (n=34) | |
|---|---|---|---|---|---|
|
| |||||
| Median age, years (range) | 61 (50–75) | 73.5 (52–80) | 70 (66–74) | 62 (59–78) | 65 (50–80) |
|
| |||||
| Male sex, no. (%) | 11 (69) | 4 (67) | 3 (100) | 5 (56) | 23 (68) |
|
| |||||
| Caucasian race, no. (%) | 16 (100) | 6 (100) | 3 (100) | 9 (100) | 34 (100) |
|
| |||||
| Median number of prior therapies, no. (range) | 3.5 (1–8) | 3.5 (1–8) | 4 (1–11) | 6 (3–14) | 4 (1–14) |
|
| |||||
| Number of prior therapies, no. (%) | |||||
| 1 | 3 (19) | 1 (17) | 1 (33) | 0 (0) | 5 (15) |
| 2 | 2 (13) | 1 (17) | 0 (0) | 0 (0) | 3 (9) |
| 3–8 | 11 (69) | 4 (67) | 1 (33) | 5 (56) | 21 (62) |
| 10–14 | 0 (0) | 0 (0) | 1 (33) | 4 (44) | 5 (15) |
|
| |||||
| Prior ibrutinib therapy, no. (%) | 11 (69) | 0 (0) | 1 (33) | 8 (89) | 20 (59) |
|
| |||||
| Prior acalabrutinib therapy, no. (%) | 1 (6) | 0 (0) | 0 (0) | 0 (0) | 1 (3) |
|
| |||||
| Prior venetoclax therapy, no. (%) | 1 (6) | 0 (0) | 1 (33) | 3 (33) | 5 (15) |
|
| |||||
| Prior idelalisib therapy, no. (%) | 2 (13) | 1 (17) | 0 (0) | 2 (22) | 5 (15) |
|
| |||||
| Prior autologous stem cell transplant, no. (%) | 1 (6) | 2 (33) | 1 (33) | 1 (11) | 5 (15) |
|
| |||||
| Prior allogeneic stem cell transplant, no. (%) | 1 (6) | 0 (0) | 0 (0) | 1 (11) | 2 (6) |
|
| |||||
| Del(11q) | 7 (44) | NA | NA | NA | NA |
|
| |||||
| Del(17p) | 4 (25) | NA | NA | NA | NA |
|
| |||||
| Unmutated IgVH | 16 (100) | NA | NA | NA | NA |
|
| |||||
| Complex karyotype | 13 (81) | NA | NA | NA | NA |
|
| |||||
| BTK Mutation | 10** | NA | NA | NA | NA |
*
1 GCB, 2 non GCB subtype, 3 not evaluated
**
9 C481S, 1 C481R/C481S, 6 not evaluated or unknown.
BTK=Bruton’s tyrosine kinase, CLL=chronic lymphocytic leukemia, DLBCL=diffuse large B-cell lymphoma, GCB=germinal center B-cell, MCL=mantle cell lymphoma